Many excellent reviews have already detailed the industry’s declining R&D productivity, increasing development costs, decreasing pipeline and lower earnings. Many more highlight prominent initiatives to bolster pipelines and cut costs. However, there is also something new percolating within biopharma companies — a growing sense that traditional cost-cutting and productivity enhancement methods may have largely run their course — and the emergence of novel “risk-based” solutions.